Open AccessDifferent ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors
Author(s) -
JeanFrançois Chatal,
François Davodeau,
Michel Chérel,
Jacques Barbet
Publication year - 2009
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.55139
Subject(s) - radioimmunotherapy , pretargeting , medicine , solid tumor , cancer research , radioresistance , alpha particle , lymphoma , hodgkin lymphoma , medical physics , α particles , nuclear medicine , radiation therapy , immunology , cancer , physics , atomic physics , monoclonal antibody , antibody
Radioimmunotherapy (RIT) has been proven effective in the treatment of radiosensitive non-Hodgkin lymphoma but, for radioresistant solid tumors, new approaches are necessary to improve the clinical effectiveness. A real improvement has been the introduction of the pretargeting technology which appeared to be able to significantly increase tumor-to-normal organ uptake ratios.Another very promising approach consists in associating RIT with other treatment modalities. Finally the use of alpha particle-emitting radionuclides such as astatin-211 or bismuth-213 (alpha-RIT) should allow to efficiently eradicate disseminated microscopic clusters of tumor cells or isolated tumor cells which fit well with the short path length of alpha particles.